This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Harms, K. L. Articles by Chen, X. Search for Related Content PubMed PubMed Citation Articles by Harms, K. L. Articles by Chen, X.

Histone Deacetylase 2 Modulates p53 Transcriptional Activities through Regulation of p53-DNA Binding Activity

Department of Cell Biology, University of Alabama at Birmingham, Birmingham, Alabama

Requests for reprints: Xinbin Chen, Center for Comparative Oncology, 2128 Tupper Hall, University of California at Davis, Davis, CA 95616. E-mail: xbchen{at}ucdavis.edu.

Histone deacetylase (HDAC) inhibitors are emerging as promising cancer therapeutics. HDAC inhibitors have been found to induce cellular activities that are strikingly similar to p53-mediated responses to genotoxic stress. For example, HDAC inhibitors induce cell cycle arrest, apoptosis, and cellular senescence. Because at least 11 HDACs are affected by the current HDAC inhibitors, the HDAC critical for tumor cell survival and proliferation remains unknown. Thus, we sought to characterize the distinct roles of HDACs in the p53 pathway. Through the use of stable MCF7 cell lines which inducibly express short hairpin RNA targeting HDAC2, we found that HDAC2 plays important roles in the p53 pathway. Specifically, we found that knockdown of HDAC2 inhibited cellular proliferation in a dose-dependent manner which was also partly p53-dependent. Furthermore, knockdown of HDAC2 induced cellular senescence. Importantly, we found that knockdown of HDAC2 enhanced p53-dependent trans-repression and trans-activation of a subset of target genes. We found that the enhancement was due to increased p53-DNA binding activity but not alterations in p53 stability or posttranslational modification(s). Thus, for the first time, our data suggest that HDAC inhibitors function through the p53 pathway, at least in part, by activating p53-DNA binding activity. [Cancer Res 2007;67(7):3145–52]

This article has been cited by other articles:

				P. Li, H. Yao, Z. Zhang, M. Li, Y. Luo, P. R. Thompson, D. S. Gilmour, and Y. Wang Regulation of p53 Target Gene Expression by Peptidylarginine Deiminase 4 Mol. Cell. Biol., August 1, 2008; 28(15): 4745 - 4758. [Abstract] [Full Text] [PDF]

				M. Dokmanovic, C. Clarke, and P. A. Marks Histone Deacetylase Inhibitors: Overview and Perspectives Mol. Cancer Res., October 1, 2007; 5(10): 981 - 989. [Abstract] [Full Text] [PDF]